Payment overview · 2025
General Payments
$767.83
33 reported records · 14 companies
Healthcare provider profile · identity verified
Mohammad Suhail, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LINCOLN, RI · NPI 1255694451
Verified facts
What the public records show
CMS Open Payments records show Mohammad Suhail, MD received $767.83 in general payments during 2025 across 33 reported records.
ABBVIE INC. accounted for 21.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Rexulti.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Linzess by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 1301 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 472 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 166 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Rexulti by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 1301 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Paxlovid by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Xifaxan by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Austedo by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $164.97 | 21.5% | 9 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $98.24 | 12.8% | 4 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $72.20 | 9.4% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $70.84 | 9.2% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $64.52 | 8.4% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $54.19 | 7.1% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $48.91 | 6.4% | 2 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $47.45 | 6.2% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $29.41 | 3.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $28.42 | 3.7% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $24.08 | 3.1% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $22.96 | 3.0% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $20.91 | 2.7% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $20.73 | 2.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $725.33 | 32 |
| Education | $42.50 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $135.30 | 8 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $119.75 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $103.69 | 5 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $98.24 | 4 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $72.20 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $64.52 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $54.19 | 2 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $47.45 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $29.67 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $29.41 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAMAX Normalized: vyndamax |
Drug | PFIZER INC. | $28.42 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $24.08 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $22.96 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $20.91 | 1 | 2025 |
Source payment records
|
|||||
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $20.73 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 1301 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 67 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
73 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1301 | 178 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
472 | 76 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
166 | 24 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
67 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
67 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1301 | 178 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
17 | 17 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
79 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
70 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 2598 | 577 |
| Trazodone Hcl | Trazodone Hcl | 1465 | 300 |
| Amlodipine Besylate | Amlodipine Besylate | 1368 | 309 |
| Eliquis | Apixaban | 1301 | 178 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1227 | 246 |
| Gabapentin | Gabapentin | 1174 | 203 |
| Furosemide | Furosemide | 1148 | 237 |
| Lisinopril | Lisinopril | 1140 | 234 |
| Sertraline Hcl | Sertraline Hcl | 1066 | 188 |
| Losartan Potassium | Losartan Potassium | 886 | 208 |
| Metformin Hcl | Metformin Hcl | 867 | 179 |
| Quetiapine Fumarate | Quetiapine Fumarate | 848 | 127 |
| Pantoprazole Sodium | Pantoprazole Sodium | 767 | 191 |
| Metoprolol Tartrate | Metoprolol Tartrate | 743 | 173 |
| Metoprolol Succinate | Metoprolol Succinate | 731 | 154 |
| Mirtazapine | Mirtazapine | 722 | 135 |
| Escitalopram Oxalate | Escitalopram Oxalate | 719 | 130 |
| Tamsulosin Hcl | Tamsulosin Hcl | 714 | 162 |
| Omeprazole | Omeprazole | 551 | 154 |
| Jardiance | Empagliflozin | 472 | 76 |
| Donepezil Hcl | Donepezil Hcl | 446 | 74 |
| Potassium Chloride | Potassium Chloride | 436 | 93 |
| Simvastatin | Simvastatin | 413 | 86 |
| Famotidine | Famotidine | 389 | 104 |
| Duloxetine Hcl | Duloxetine Hcl | 363 | 81 |
| Levetiracetam | Levetiracetam | 342 | 53 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 314 | 63 |
| Citalopram Hbr | Citalopram Hydrobromide | 294 | 54 |
| Hydrochlorothiazide | Hydrochlorothiazide | 292 | 77 |
| Divalproex Sodium | Divalproex Sodium | 275 | 37 |
| Xarelto | Rivaroxaban | 273 | 38 |
| Pravastatin Sodium | Pravastatin Sodium | 267 | 68 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 250 | 51 |
| Warfarin Sodium | Warfarin Sodium | 247 | 17 |
| Atenolol | Atenolol | 244 | 47 |
| Carvedilol | Carvedilol | 240 | 69 |
| Prednisone | Prednisone | 237 | 95 |
| Risperidone | Risperidone | 236 | 37 |
| Fluoxetine Hcl | Fluoxetine Hcl | 234 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 233 | 60 |
| Fluticasone Propionate | Fluticasone Propionate | 232 | 85 |
| Olanzapine | Olanzapine | 229 | 38 |
| Montelukast Sodium | Montelukast Sodium | 225 | 50 |
| Lactulose | Lactulose | 211 | 28 |
| Alendronate Sodium | Alendronate Sodium | 210 | 39 |
| Ondansetron Hcl | Ondansetron Hcl | 205 | 98 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 204 | 35 |
| Memantine Hcl | Memantine Hcl | 202 | 37 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 188 | 52 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 184 | 92 |
| Diclofenac Sodium | Diclofenac Sodium | 180 | 49 |
| Sucralfate | Sucralfate | 177 | 28 |
| Meloxicam | Meloxicam | 171 | 28 |
| Latanoprost | Latanoprost | 170 | 42 |
| Bumetanide | Bumetanide | 168 | 40 |
| Finasteride | Finasteride | 167 | 41 |
| Tradjenta | Linagliptin | 166 | 11 |
| Trulicity | Dulaglutide | 166 | 24 |
| Incruse Ellipta | Umeclidinium Bromide | 165 | 21 |
| Baclofen | Baclofen | 156 | 26 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 155 | 49 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 154 | 66 |
| Buspirone Hcl | Buspirone Hcl | 146 | 28 |
| Aripiprazole | Aripiprazole | 143 | 24 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 141 | 32 |
| Lamotrigine | Lamotrigine | 133 | 16 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 128 | 31 |
| Bupropion Xl | Bupropion Hcl | 123 | 28 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 123 | 23 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 120 | 79 |
| Spironolactone | Spironolactone | 120 | 48 |
| Hydralazine Hcl | Hydralazine Hcl | 119 | 33 |
| Paroxetine Hcl | Paroxetine Hcl | 117 | 25 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 115 | 25 |
| Glipizide | Glipizide | 113 | 32 |
| Allopurinol | Allopurinol | 110 | 41 |
| Benztropine Mesylate | Benztropine Mesylate | 105 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 103 | 58 |
| Metformin Hcl Er | Metformin Hcl | 101 | 32 |
| Ezetimibe | Ezetimibe | 99 | 32 |
| Insulin Lispro | Insulin Lispro | 99 | 27 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 97 | 22 |
| Amitriptyline Hcl | Amitriptyline Hcl | 94 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 94 | 22 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 93 | 24 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 92 | 24 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 92 | 23 |
| Labetalol Hcl | Labetalol Hcl | 91 | 13 |
| Brilinta | Ticagrelor | 90 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 90 | 39 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 90 | 34 |
| Ceftriaxone | Ceftriaxone Sodium | 88 | 50 |
| Ibuprofen | Ibuprofen | 88 | 29 |
| Lovastatin | Lovastatin | 88 | 21 |
| Topiramate | Topiramate | 88 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 83 | 53 |
| Januvia | Sitagliptin Phosphate | 82 | suppressed |
| Cephalexin | Cephalexin | 81 | 54 |
| Albuterol Sulfate | Albuterol Sulfate | 80 | 43 |
| Humalog Kwikpen U-100 | Insulin Lispro | 80 | 24 |
| Lidocaine Hcl | Lidocaine Hcl | 80 | 53 |
| Oxybutynin Chloride | Oxybutynin Chloride | 80 | 17 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 80 | 33 |
| Xifaxan | Rifaximin | 79 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 77 | 18 |
| Glimepiride | Glimepiride | 75 | 29 |
| Nystatin | Nystatin | 75 | 48 |
| Torsemide | Torsemide | 75 | 15 |
| Chlorthalidone | Chlorthalidone | 74 | 17 |
| Brimonidine Tartrate | Brimonidine Tartrate | 73 | 14 |
| Creon | Lipase/Protease/Amylase | 73 | suppressed |
| Digoxin | Digoxin | 73 | 19 |
| Sodium Chloride | 0.9 % Sodium Chloride | 71 | 43 |
| Austedo | Deutetrabenazine | 70 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 69 | 21 |
| Ramelteon | Ramelteon | 68 | 14 |
| Rexulti | Brexpiprazole | 67 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 66 | 47 |
| Myrbetriq | Mirabegron | 63 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 63 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 62 | 18 |
| Haloperidol | Haloperidol | 62 | suppressed |
| Azithromycin | Azithromycin | 61 | 35 |
| Clozapine | Clozapine | 59 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 59 | 17 |
| Venlafaxine Hcl | Venlafaxine Hcl | 59 | suppressed |
| Glipizide Er | Glipizide | 57 | 16 |
| Meclizine Hcl | Meclizine Hcl | 57 | 26 |
| Midodrine Hcl | Midodrine Hcl | 57 | 17 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 55 | 30 |
| Ropinirole Hcl | Ropinirole Hcl | 54 | 14 |
| Methocarbamol | Methocarbamol | 53 | 21 |
| Entresto | Sacubitril/Valsartan | 52 | 13 |
| Levofloxacin | Levofloxacin | 52 | 35 |
| Cinacalcet Hcl | Cinacalcet Hcl | 51 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 51 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 49 | 17 |
| Otezla | Apremilast | 49 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 48 | 13 |
| Metoclopramide Hcl | Metoclopramide Hcl | 48 | 11 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 48 | 22 |
| Lorazepam | Lorazepam | 46 | 31 |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 46 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 44 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 44 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 44 | 22 |
| Symbicort | Budesonide/Formoterol Fumarate | 43 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 42 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 42 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 41 | 12 |
| Prednisolone Acetate | Prednisolone Acetate | 41 | 12 |
| Cefuroxime | Cefuroxime Axetil | 40 | 26 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 40 | 11 |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 40 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 40 | 22 |
| Valsartan | Valsartan | 40 | 12 |
| Ertapenem | Ertapenem Sodium | 39 | 19 |
| Farxiga | Dapagliflozin Propanediol | 39 | suppressed |
| Carbamazepine | Carbamazepine | 38 | suppressed |
| Verapamil Er | Verapamil Hcl | 38 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 37 | 14 |
| Ketoconazole | Ketoconazole | 37 | 22 |
| Nebivolol Hcl | Nebivolol Hcl | 37 | suppressed |
| Paliperidone Er | Paliperidone | 37 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 36 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 36 | suppressed |
| Humalog | Insulin Lispro | 36 | 13 |
| Irbesartan | Irbesartan | 36 | suppressed |
| Silodosin | Silodosin | 36 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 35 | 14 |
| Mupirocin | Mupirocin | 35 | 24 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 35 | suppressed |
| Primidone | Primidone | 35 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 35 | 18 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 34 | 14 |
| Nifedipine Er | Nifedipine | 34 | 13 |
| Scopolamine | Scopolamine | 34 | suppressed |
| Ssd | Silver Sulfadiazine | 34 | 13 |
| Celecoxib | Celecoxib | 33 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 33 | 13 |
| Lithium Carbonate | Lithium Carbonate | 33 | suppressed |
| Cefdinir | Cefdinir | 32 | 20 |
| Metronidazole | Metronidazole | 32 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 32 | suppressed |
| Timolol Maleate | Timolol Maleate | 32 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 31 | suppressed |
| Fluconazole | Fluconazole | 31 | 24 |
| Admelog Solostar | Insulin Lispro | 30 | 13 |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 30 | 19 |
| Gemtesa | Vibegron | 30 | suppressed |
| Amoxicillin | Amoxicillin | 29 | 17 |
| Erythromycin | Erythromycin Base | 29 | 24 |
| Kapspargo Sprinkle | Metoprolol Succinate | 29 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 29 | suppressed |
| Linzess | Linaclotide | 29 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 29 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 28 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 28 | 18 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 28 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 28 | suppressed |
| Constulose | Lactulose | 27 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 27 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 27 | suppressed |
| Lidocaine | Lidocaine | 26 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 26 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 26 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 26 | suppressed |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 25 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 25 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 25 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 24 | suppressed |
| Entacapone | Entacapone | 24 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 24 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 24 | suppressed |
| Ranolazine Er | Ranolazine | 24 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 23 | suppressed |
| Methotrexate | Methotrexate Sodium | 23 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 23 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 22 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 22 | 21 |
| Azelastine Hcl | Azelastine Hcl | 22 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 22 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 22 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 22 | 11 |
| Nitroglycerin | Nitroglycerin | 22 | 17 |
| Sevelamer Carbonate | Sevelamer Carbonate | 22 | suppressed |
| Lubiprostone | Lubiprostone | 21 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 21 | suppressed |
| Phenytoin | Phenytoin | 21 | suppressed |
| Vancomycin Hcl | Vancomycin/Water For Inj (Peg) | 21 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 20 | suppressed |
| Dulera | Mometasone/Formoterol | 20 | suppressed |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 20 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 20 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 20 | 17 |
| Dorzolamide Hcl | Dorzolamide Hcl | 19 | suppressed |
| Letrozole | Letrozole | 19 | suppressed |
| Levemir | Insulin Detemir | 19 | suppressed |
| Nyamyc | Nystatin | 19 | 16 |
| Oxcarbazepine | Oxcarbazepine | 19 | suppressed |
| Verapamil Sr | Verapamil Hcl | 19 | suppressed |
| Alprazolam | Alprazolam | 18 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 18 | suppressed |
| Folic Acid | Folic Acid | 18 | 11 |
| Ozempic | Semaglutide | 18 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 18 | suppressed |
| Calcitriol | Calcitriol | 17 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 17 |
| Pilocarpine Hcl | Pilocarpine Hcl | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 16 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 16 | suppressed |
| Ursodiol | Ursodiol | 16 | suppressed |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Indapamide | Indapamide | 15 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 15 | suppressed |
| Linezolid | Linezolid | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 15 | 13 |
| Permethrin | Permethrin | 15 | suppressed |
| Rhopressa | Netarsudil Mesylate | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 15 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 14 | suppressed |
| Dexamethasone | Dexamethasone | 14 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 14 | suppressed |
| Haloperidol Lactate | Haloperidol Lactate | 14 | suppressed |
| Levemir Flexpen | Insulin Detemir | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Travoprost | Travoprost | 14 | suppressed |
| Acetazolamide | Acetazolamide | 13 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Glucagon Emergency Kit | Glucagon | 13 | 11 |
| Hydrocortisone | Hydrocortisone | 13 | 12 |
| Leflunomide | Leflunomide | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Budesonide | Budesonide | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 12 | suppressed |
| Exemestane | Exemestane | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 12 | suppressed |
| Lamotrigine Er | Lamotrigine | 12 | suppressed |
| Levocarnitine | Levocarnitine | 12 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 12 | suppressed |
| Xiidra | Lifitegrast | 12 | suppressed |
| Cromolyn Sodium | Cromolyn Sodium | 11 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 11 | suppressed |
| Imipenem-Cilastatin Sodium | Imipenem/Cilastatin Sodium | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Securesafe Pen Needle | Pen Needle, Diabetic, Safety | 11 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $767.83 · 33 records | ABBVIE INC. | AFREZZA, AUSTEDO XR, CAPLYTA, ELIQUIS, IBSRELA, INGREZZA, KISUNLA, Kerendia, QULIPTA, RELISTOR, REXULTI, UBRELVY, VRAYLAR, VYNDAMAX, YUPELRI | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error